Online inquiry

IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2018MR)

This product GTTS-WQ2018MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets INSR gene. The antibody can be applied in Hunter syndrome (MPS II) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000208.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3643
UniProt ID P06213
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2018MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14769MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ2079MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ2311MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ13050MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ2240MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ12280MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ356MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ10136MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LAG-525
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW